Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks (Q46553509)
Jump to navigation
Jump to search
scientific article published in July 2008
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks |
scientific article published in July 2008 |
Statements
1 reference
Entecavir therapy for lamivudine-refractory chronic hepatitis B: improved virologic, biochemical, and serology outcomes through 96 weeks (English)
1 reference
Morris Sherman
1 reference
Cihan Yurdaydin
1 reference
Halis Simsek
1 reference
Marcelo Silva
1 reference
Vinod K Rustgi
1 reference
Hoel Sette
1 reference
Naoky Tsai
1 reference
Daniel J Tenney
1 reference
James Vaughan
1 reference
Bruce Kreter
1 reference
Robert Hindes
1 reference
AI463026 Benefits of Entecavir for Hepatitis B Liver Disease (BEHoLD) Study Group
1 reference
1 July 2008
1 reference
1 reference
48
1 reference
1
1 reference
99-108
1 reference
Identifiers
1 reference
1 reference